Provided by Tiger Fintech (Singapore) Pte. Ltd.

Day One Biopharmaceuticals Inc.

7.00
-0.2050-2.85%
Volume:181.29K
Turnover:1.28M
Market Cap:716.51M
PE:-7.46
High:7.18
Open:7.16
Low:7.00
Close:7.20
52wk High:16.76
52wk Low:5.64
Shares:102.43M
Float Shares:78.77M
Volume Ratio:0.41
T/O Rate:0.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9382
EPS(LYR):-1.0243
ROE:-24.75%
ROA:-15.19%
PB:1.55
PE(LYR):-6.83

Loading ...

Charles N. York II, COO and CFO, Reports Disposal of Common Shares in Day One Biopharmaceuticals Inc

Reuters
·
Aug 20

Adam Dubow, General Counsel & Secretary, Reports Disposal of Common Shares in Day One Biopharmaceuticals Inc

Reuters
·
Aug 20

Chief Commercial Officer Lauren Merendino Reports Disposal of Day One Biopharmaceuticals Inc. Common Shares

Reuters
·
Aug 20

Day One Biopharmaceuticals initiated with an Overweight at Piper Sandler

TIPRANKS
·
Aug 19

Promising Growth and Stability Drive Buy Rating for Day One Biopharmaceuticals

TIPRANKS
·
Aug 11

Day One Biopharmaceuticals Inc : JP Morgan Cuts Target Price to $26 From $29

THOMSON REUTERS
·
Aug 11

Stock Track | Day One Biopharmaceuticals Plummets 14.75% as H.C. Wainwright Slashes Price Target

Stock Track
·
Aug 06

Day One price target lowered to $25 from $36 at H.C. Wainwright

TIPRANKS
·
Aug 06

Day One Biopharmaceuticals, Inc. : H.c. Wainwright Cuts Target Price to $25 From $36

THOMSON REUTERS
·
Aug 06

Day One Biopharm Is Maintained at Buy by Needham

Dow Jones
·
Aug 06

Day One (DAWN) Q2 Revenue Jumps 313%

Motley Fool
·
Aug 06

Day One Biopharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 06

Day One Biopharmaceuticals Reports Strong Q2 2025 Results

TIPRANKS
·
Aug 06

Stock Track | Day One Biopharmaceuticals Plunges 11.34% After-Hours Despite Beating EPS Estimates

Stock Track
·
Aug 06

BRIEF-Day One Biopharmaceuticals Q2 EPS USD -0.29

Reuters
·
Aug 06

Day One Biopharma Q2 2025: OJEMDA Sales Surge 310% YoY, Net Product Revenue Hits $33.6M

Reuters
·
Aug 06

Day One Biopharmaceuticals: Ojemda FY 2025 Net Product Revenue Expected to Be $140 to $150 Mln

THOMSON REUTERS
·
Aug 06

Day One Biopharmaceuticals Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
·
Aug 02

Day One Biopharmaceuticals Inc. to Announce Second Quarter 2025 Financial Results

Reuters
·
Jul 22

We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth

Simply Wall St.
·
Jul 18